European regulators approve Cimzia

UCB has gained European approval to market Cimzia to treat rheumatoid arthritis, a decision that followed the FDA's approval in May. The decision, which was widely expected, allows UCB a much broader market for the TNF therapy, which is the fourth to hit the market behind Enbrel, Remicade and Humira. UCB is collaborating with Nektar Therapeutics, which gains royalties on sales. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.